Targeting FAK in human cancer: From finding to first clinical trials

Frontiers in Bioscience - Landmark

Volumn 19, Issue 4, 2014, Pages 687-706

  Golubovskaya, Vita M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Focal adhesion kinase; Metastasis; Review; Small molecule inhibitors; Survival

Indexed keywords

ENZYME INHIBITOR; FOCAL ADHESION KINASE;

CANCER STEM CELL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN CONFORMATION; REVIEW;

ENZYME INHIBITORS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PROTEIN CONFORMATION;

EID: 84897437048     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4236     Document Type: Review

References (155)

1. M. D. Schaller, C. A. Borgman, B. S. Cobb, R. R. Vines, A. B. Reynolds and J. T. Parsons: pp125fak a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA, 89, 5192-5196 (1992)
2. M. Luo, H. Fan, T. Nagy, H. Wei, C. Wang, S. Liu, M. S. Wicha and J. L. Guan: Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res, 69, 466-474 (2009)
3. M. Schober and E. Fuchs: Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A, 108, 10544-10549 (2009)
4. B. Ho, G. Olson, S. Figel, I. Gelman, W. G. Cance and V. M. Golubovskaya: Nanog Increases Focal Adhesion Kinase (FAK) Promoter Activity and Expression and Directly Binds to FAK Protein to Be Phosphorylated. J Biol Chem, 287, 18656-18773 (2012)
5. X. Peng, H. Ueda, H. Zhou, T. Stokol, T. L. Shen, A. Alcaraz, T. Nagy, J. D. Vassalli and J. L. Guan: Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice. Cardiovasc Res, 64, 421-430 (2004)
6. C. Scheel and R. A. Weinberg: Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer, 129, 2310-2314 (2011)
7. H. Fan, X. Zhao, S. Sun, M. Luo and J. L. Guan: Focal adhesion kinase scaffolding function to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo. J Biol Chem 288, 3322-3333 (2013)
8. A. Serrels, M. Canel, V. G. Brunton and M. C. Frame: Src/FAK-mediated regulation of E-cadherin as a mechanism for controlling collective cell movement: insights from in vivo imaging. Cell Adh Migr, 5, 360-365 (2011)
9. T. Fujii, K. Koshikawa, S. Nomoto, O. Okochi, T. Kaneko, S. Inoue, Y. Yatabe, S. Takeda and A. Nakao: Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol, 41, 104-111 (2004)
10. S. Carelli, G. Zadra, V. Vaira, M. Falleni, L. Bottiglieri, M. Nosotti, A. M. Di Giulio, A. Gorio and S. Bosari: Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer, 53, 263-271 (2006)
11. S. Ocak, H. Chen, C. Callison, A. L. Gonzalez and P. P. Massion: Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer, 118(5), 1293-1301 (2012)
12. A. L. Lark, C. A. Livasy, L. Dressler, D. T. Moore, R. C. Millikan, J. Geradts, M. Iacocca, D. Cowan, D. Little, R. J. Craven and W. Cance: High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod Pathol, 18, 1289-1294 (2005)
13. K. Furuyama, R. Doi, T. Mori, E. Toyoda, D. Ito, K. Kami, M. Koizumi, A. Kida, Y. Kawaguchi and K. Fujimoto: Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg, 30, 219-226 (2006)
14. T. P. Hecker, J. R. Grammer, G. Y. Gillespie, J. Stewart, Jr. and C. L. Gladson: Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res, 62, 2699-2707 (2002)
15. A. Gutenberg, W. Bruck, M. Buchfelder and H. C. Ludwig: Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol, 108, 224-30 (2004)
16. L. V. Owens, L. Xu, R. J. Craven, G. A. Dent, T. M. Weiner, L. Kornberg, E. T. Liu and W. G. Cance: Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Research, 55, 2752-2755 (1995)
17. A. Schroder, G. Delling and E. A. Kaiser: [Expression analysis of protein tyrosine kinases of the FAK (focal adhesion kinase) family in osteosarcoma]. Pathologe, 23, 361-366 (2002)
18. P. L. Judson, X. He, W. G. Cance and L. Van Le: Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer, 86, 1551-1556 (1999)
19. M. H. Oktay, K. Oktay, D. Hamele-Bena, A. Buyuk and L. G. Koss: Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas. Hum Pathol, 34, 240-245 (2003)
20. H. S. Moon, W. I. Park, E. A. Choi, H. W. Chung and S. C. Kim: The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer, 13, 640-646 (2003)
21. A. L. Lark, C. A. Livasy, B. Calvo, L. Caskey, D. T. Moore, X. Yang and W. G. Cance: Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res, 9, 215-222 (2003)
22. S. E. Theocharis, G. P. Kouraklis, J. D. Kakisis, H. G. Kanelli, F. E. Apostolakou, G. M. Karatzas and A. S. Koutselinis: Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients. Eur J Surg Oncol, 29, 571-574 (2003)
23. E. A. Beierle, N. A. Massoll, J. Hartwich, E. V. Kurenova, V. M. Golubovskaya, W. G. Cance, P. McGrady and W. B. London: Focal Adhesion Kinase Expression in Human Neuroblastoma: Immunohistochemical and Real-time PCR Analyses. Clin Cancer Res, 14, 3299-3305 (2008)
24. L. V. Owens, L. Xu, G. A. Dent, X. Yang, G. C. Sturge, R. J. Craven and W. G. Cance: Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Annals of Surgical Oncology, 3, 100-105 (1996)
25. L. Tremblay, W. Hauck, A. G. Aprikian, L. R. Begin, A. Chapdelaine and S. Chevalier: Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer, 68, 164-171 (1996)
26. M. Canel, P. Secades, J.-P. Rodrigo, R. Cabanillas, A. Herrero, C. Suarez and M.-D. Chiara: Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number. Clin Cancer Res 1583, 12, 3272-3279 (2006)
27. C. Recher, L. Ysebaert, O. Beyne-Rauzy, V. Mansat-De Mas, J.-B. Ruidavets, P. Cariven, C. Demur, B. Payrastre, G. Laurent and C. Racaud-Sultan: Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis. Cancer Res, 64, 3191-3197 (2004)
28. H. M. Lightfoot, Jr., A. Lark, C. A. Livasy, D. T. Moore, D. Cowan, L. Dressler, R. J. Craven and W. G. Cance: Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat, 88, 109-116 (2004)
29. V. Gabarra-Niecko, M. D. Schaller and J. M. Dunty: FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev, 22(4), 359-374 (2003)
30. G. W. McLean, E. Avizienyte and M. C. Frame: Focal adhesion kinase as a potential target in oncology. Expert Opin Pharmacother, 4, 227-234 (2003)
31. J. R. Infante, D. R. Camidge, L. R. Mileshkin, E. X. Chen, R. J. Hicks, D. Rischin, H. Fingert, K. J. Pierce, H. Xu, W. G. Roberts, S. M. Shreeve, H. A. Burris and L. L. Siu: Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol, 30, 1527-1533 (2012)
32. S. K. Hanks, M. B. Calalb, M. C. Harper and S. K. Patel: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proceedings of the National Academy of Sciences of the United States of America, 89, 8487-8491 (1992)
33. G. S. Whitney, P. Y. Chan, J. Blake, W. L. Cosand, M. G. Neubauer, A. Aruffo and S. B. Kanner: Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK. DNA & Cell Biology, 12, 823-830 (1993)
34. T. M. Weiner, E. T. Liu, R. J. Craven and W. G. Cance: Expression of focal adhesion kinase gene and invasive cancer. Lancet, 342, 1024-1025 (1993)
35. R. H. Palmer, L. I. Fessler, P. T. Edeen, S. J. Madigan, M. McKeown and T. Hunter: DFak56 is a novel Drosophila melanogaster focal adhesion kinase. J Biol Chem, 274, 35621-35629 (1999)
36. J. Fujimoto, K. Sawamoto, M. Okabe, Y. Takagi, T. Tezuka, S. Yoshikawa, H. Ryo, H. Okano and T. Yamamoto: Cloning and characterization of Dfak56, a homolog of focal adhesion kinase, in Drosophila melanogaster. J Biol Chem, 274, 29196-29201 (1999)
37. G. L. Fox, I. Rebay and R. O. Hynes: Expression of DFak56, a Drosophila homolog of vertebrate focal adhesion kinase, supports a role in cell migration in vivo. Proc Natl Acad Sci U S A, 96, 14978-14983 (1999)
38. W. G. Cance, E. Kurenova, T. Marlowe and V. Golubovskaya: Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics. Sci Signal, 6, pe10 (2013)
39. J. M. Corsi, E. Rouer, J. A. Girault and H. Enslen: Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics, 7, 198-201 (2006)
40. M. Agochiya, V. G. Brunton, D. W. Owens, E. K. Parkinson, C. Paraskeva, W. N. Keith and M. C. Frame: Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells [In Process Citation]. Oncogene, 18, 5646-5653 (1999)
41. H. Okamoto, K. Yasui, C. Zhao, S. Arii and J. Inazawa: PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology, 38, 1242-1249 (2003)
42. V. Golubovskaya, A. Kaur and W. Cance: Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim Biophys Acta, 1678, 111-125 (2004)
43. M. D. Schaller, J. D. Hildebrand, J. D. Shannon, J. W. Fox, R. R. Vines and J. T. Parsons: Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Molecular & Cellular Biology, 14, 1680-1688 (1994)
44. C. R. Hauck, D. J. Sieg, D. A. Hsia, J. C. Loftus, W. A. Gaarde, B. P. Monia and D. D. Schlaepfer: Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res, 61, 7079-7090 (2001)
45. G. Kadare, M. Toutant, E. Formstecher, J. C. Corvol, M. Carnaud, M. C. Boutterin and J. A. Girault: PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J Biol Chem, 278(48), 47434-47440 (2003)
46. T. Eskildsen, H. Taipaleenmaki, J. Stenvang, B. M. Abdallah, N. Ditzel, A. Y. Nossent, M. Bak, S. Kauppinen and M. Kassem: MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc Natl Acad Sci U S A, 108, 6139-6144
47. V. M. Golubovskaya, B. Sumbler, B. Ho, M. Yemma and W. G. Cance: MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells. Anticancer Agents Med Chem (2013)
48. X. Kong, G. Li, Y. Yuan, Y. He, X. Wu, W. Zhang, Z. Wu, T. Chen, W. Wu, P. E. Lobie and T. Zhu: MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One, 7, e41523 (2012)
49. V. Ossovskaya, S.-T. Lim, N. Ota, D. D. Schlaepfer and D. Ilic: FAK nuclear export signal sequences. FEBS Letters, 582, 2402-2404 (2008)
50. V. M. Golubovskaya, R. Finch and W. G. Cance: Direct Interaction of the N-terminal Domain of Focal Adhesion Kinase with the N-terminal Transactivation Domain of p53. J. Biol. Chem., 280, 25008-25021 (2005)
51. S. T. Lim, X. L. Chen, Y. Lim, D. A. Hanson, T. T. Vo, K. Howerton, N. Larocque, S. J. Fisher, D. D. Schlaepfer and D. Ilic: Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell, 29, 9-22 (2008)
52. S. T. Lim: Nuclear FAK: a new mode of gene regulation from cellular adhesions. Mol Cells, 36, 1-6 (2013)
53. W. G. Cance and V. M. Golubovskaya: Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal, 1, pe22 (2008)
54. S. T. Arold, M. K. Hoellerer and M. E. Noble: The structural basis of localization and signaling by the focal adhesion targeting domain. Structure, 10, 319-327 (2002)
55. I. Hayashi, K. Vuori and R. C. Liddington: The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struct Biol, 9, 101-106 (2002)
56. D. F. Ceccarelli, H. K. Song, F. Poy, M. D. Schaller and M. J. Eck: Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem, 281, 252-259 (2006)
57. J. Nowakowski, C. N. Cronin, D. E. McRee, M. W. Knuth, C. G. Nelson, N. P. Pavletich, J. Rogers, B. C. Sang, D. N. Scheibe, R. V. Swanson and D. A. Thompson: Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure, 10, 1659-1667 (2002)
58. D. Lietha, X. Cai, D. F. Ceccarelli, Y. Li, M. D. Schaller and M. J. Eck: Structural basis for the autoinhibition of focal adhesion kinase. Cell, 129, 1177-1187 (2007)
59. J. T. Parsons: Focal adhesion kinase: the first ten years. J Cell Sci, 116, 1409-1416 (2003)
60. M. D. Schaller: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta, 1540, 1-21 (2001)
61. J. L. Guan: Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life, 62, 268-276 (2010)
62. V. M. Golubovskaya and W. G. Cance: Focal adhesion kinase and p53 signaling in cancer cells. Int Rev Cytol, 263, 103-153 (2007)
63. D. D. Schlaepfer, C. R. Hauck and D. J. Sieg: Signaling through focal adhesion kinase. Prog Biophys Mol Biol, 71(3-4), 435-478 (1999)
64. S. M. Frisch, K. Vuori, E. Ruoslahti and P. Y. Chan-Hui: Control of adhesion-dependent cell survival by focal adhesion kinase. Journal of Cell Biology, 134, 793-799 (1996)
65. L. H. Xu, L. V. Owens, G. C. Sturge, X. Yang, E. T. Liu, R. J. Craven and W. G. Cance: Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ, 7, 413-418 (1996)
66. L.-h. Xu, X.-h. Yang, C. A. Bradham, D. A. Brenner, A. S. Baldwin, R. J. Craven and W. G. Cance: The focal adhesion kinase suppresses transformation-associated, anchorage-Independent apoptosis in human breast cancer cells. J. Biol. Chem., 275, 30597-30604 (2000)
67. V. M. Golubovskaya, M. Zheng, L. Zhang, J. L. Li and W. G. Cance: The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer, 9, 280-285 (2009)
68. E. Kurenova, L.-H. Xu, X. Yang, A. S. Baldwin, Jr., R. J. Craven, S. K. Hanks, Z.-g. Liu and W. G. Cance: Focal Adhesion Kinase Suppresses Apoptosis by Binding to the Death Domain of Receptor-Interacting Protein. Mol. Cell. Biol., 24, 4361-4371 (2004)
69. Y. Sonoda, Y. Matsumoto, M. Funakoshi, D. Yamamoto, S. K. Hanks and T. Kasahara: Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem, 275, 16309-16315 (2000)
70. J. Schwock, N. Dhani, M. P. Cao, J. Zheng, R. Clarkson, N. Radulovich, R. Navab, L. C. Horn and D. W. Hedley: Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts. Cancer Res, 69, 4750-4759 (2009)
71. E. Sandilands, B. Serrels, D. G. McEwan, J. P. Morton, J. P. Macagno, K. McLeod, C. Stevens, V. G. Brunton, W. Y. Langdon, M. Vidal, O. J. Sansom, I. Dikic, S. Wilkinson and M. C. Frame: Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling. Nat Cell Biol, 14, 51-60 (2012)
72. D. D. Schlaepfer, S. K. Mitra and D. Ilic: Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta, 1692(2-3), 77-102 (2004)
73. D. J. Sieg, C. R. Hauck and D. D. Schlaepfer: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci, 112, 2677-2691 (1999)
74. D. Illc, Y. Furuta, S. Kanazawa, N. Takeda, K. Sobue, N. Nakatsuji, S. Nomura, J. Fujimoto, M. Okada, T. Yamamoto and et al.: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature, 377, 539-544 (1995)
75. M. G. Yeo, M. A. Partridge, E. J. Ezratty, Q. Shen, G. G. Gundersen and E. E. Marcantonio: Src SH2 arginine 175 is required for cell motility: specific focal adhesion kinase targeting and focal adhesion assembly function. Mol Cell Biol, 26, 4399-4409 (2006)
76. H. R. Reiske, S. C. Kao, L. A. Cary, J. L. Guan, J. F. Lai and H. C. Chen: Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol Chem, 274, 12361-12366 (1999)
77. T. Shibue and R. A. Weinberg: Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A, 106, 10290-10295 (2009)
78. S. M. Frisch, M. Schaller and B. Cieply: Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci, 126, 21-29 (2013)
79. M. Canel, A. Serrels, M. C. Frame and V. G. Brunton: E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci, 126, 393-401 (2013)
80. E. Avizienyte, A. W. Wyke, R. J. Jones, G. W. McLean, M. A. Westhoff, V. G. Brunton and M. C. Frame: Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol, 4, 632-638 (2002)
81. C. R. Hauck, D. A. Hsia and D. D. Schlaepfer: The focal adhesion kinase - a regulator of cell migration and invasion. IUBMB Life, 53, 115-119 (2002)
82. D. Saito, S. Kyakumoto, N. Chosa, M. Ibi, N. Takahashi, N. Okubo, S. Sawada, A. Ishisaki and M. Kamo: Transforming growth factor-beta1 induces epithelial-mesenchymal transition and integrin alpha3beta1-mediated cell migration of HSC-4 human squamous cell carcinoma cells through Slug. J Biochem, 153, 303-315 (2013)
83. T. Lechertier and K. Hodivala-Dilke: Focal adhesion kinase and tumour angiogenesis. J Pathol, 226, 404-412 (2012)
84. R. Guinamard, M. Okigaki, J. Schlessinger and J. V. Ravetch: Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol, 1, 31-36 (2000)
85. S. K. Mitra, D. Mikolon, J. E. Molina, D. A. Hsia, D. A. Hanson, A. Chi, S. T. Lim, J. A. Bernard-Trifilo, D. Ilic, D. G. Stupack, D. A. Cheresh and D. D. Schlaepfer: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. 25, 5969-5984 Oncogene (2006)
86. C. A. Garces, E. V. Kurenova, V. M. Golubovskaya and W. G. Cance: Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res, 66, 1446-1454 (2006)
87. M. Dean, T. Fojo and S. Bates: Tumour stem cells and drug resistance. Nat Rev Cancer, 5, 275-284 (2005)
88. Y. Li and J. Laterra: Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res, 72, 576-580 (2012)
89. G. H. Ashton, J. P. Morton, K. Myant, T. J. Phesse, R. A. Ridgway, V. Marsh, J. A. Wilkins, D. Athineos, V. Muncan, R. Kemp, K. Neufeld, H. Clevers, V. Brunton, D. J. Winton, X. Wang, R. C. Sears, A. R. Clarke, M. C. Frame and O. J. Sansom: Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell, 19, 259-269 (2010)
90. Y. Fonar, Y. E. Gutkovich, H. Root, A. Malyarova, E. Aamar, V. M. Golubovskaya, S. Elias, Y. M. Elkouby and D. Frank: Focal adhesion kinase protein regulates Wnt3a gene expression to control cell fate specification in the developing neural plate. Mol Biol Cell, 22, 2409-2421 (2011)
91. Y. Fonar and D. Frank: FAK and WNT signaling: the meeting of two pathways in cancer and development. Anticancer Agents Med Chem, 11, 600-606 (2011)
92. H. Fan and J. L. Guan: Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. J Biol Chem, 286, 18573-15582 (2011)
93. M. Luo, X. Zhao, S. Chen, S. Liu, M. S. Wicha and J. L. Guan: Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res 73, 5591-5602 (2013)
94. S. D. Wang, P. Rath, B. Lal, J. P. Richard, Y. Li, C. R. Goodwin, J. Laterra and S. Xia: EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene 31, 5132-5143 (2012)
95. J. S. Chen, X. H. Huang, Q. Wang, J. Q. Huang, L. J. Zhang, X. L. Chen, J. Lei and Z. X. Cheng: Sonic hedgehog signaling pathway induces cell migration and invasion through focal adhesion kinase/AKT signaling-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 in liver cancer. Carcinogenesis, 34, 10-19 (2013)
96. J. Wang, L. Fu, F. Gu and Y. Ma: Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep, 26(5), 1295-1303 (2011)
97. Y. L. Lin, Z. B. Han, F. Y. Xiong, L. Y. Tian, X. J. Wu, S. W. Xue, Y. R. Zhou, J. X. Deng and H. X. Chen: Malignant transformation of 293 cells induced by ectopic expression of human Nanog. Mol Cell Biochem, 351, 109-116 (2011)
98. T. Lin, C. Chao, S. Saito, S. J. Mazur, M. E. Murphy, E. Appella and Y. Xu: p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol, 7, 165-71 (2005)
99. V. Krizhanovsky and S. W. Lowe: Stem cells: The promises and perils of p53. Nature, 460, 1085-1086 (2009)
100. H. Hong, K. Takahashi, T. Ichisaka, T. Aoi, O. Kanagawa, M. Nakagawa, K. Okita and S. Yamanaka: Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature, 460, 1132-1135 (2009)
101. T. Kawamura, J. Suzuki, Y. V. Wang, S. Menendez, L. B. Morera, A. Raya, G. M. Wahl and J. C. Izpisua Belmonte: Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature, 460, 1140-1144 (2009)
102. R. M. Marion, K. Strati, H. Li, M. Murga, R. Blanco, S. Ortega, O. Fernandez-Capetillo, M. Serrano and M. A. Blasco: A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 460, 1149-1153 (2009)
103. V. M. Golubovskaya, R. Finch, F. Kweh, N. A. Massoll, M. Campbell-Thompson, M. R. Wallace and W. G. Cance: p53 regulates FAK expression in human tumor cells. Mol Carcinog, 47, 373-382 (2008)
104. K. Kobayashi, H. Takahashi, A. Inoue, H. Harada, S. Toshimori, Y. Kobayashi, K. Goto, K. Sugimoto, H. Yano, T. Ohnishi and J. Tanaka: Oct-3/4 promotes migration and invasion of glioblastoma cells. J Cell Biochem, 113, 508-517 (2012)
105. S. I. Grivennikov, F. R. Greten and M. Karin: Immunity, inflammation, and cancer. Cell, 140, 883-899 (2010)
106. M. Y. Abshire, K. S. Thomas, K. A. Owen and A. H. Bouton: Macrophage motility requires distinct alpha5beta1/FAK and alpha4beta1/paxillin signaling events. J Leukoc Biol, 89, 251-257 (2011)
107. D. D. Schlaepfer, S. Hou, S. T. Lim, A. Tomar, H. Yu, Y. Lim, D. A. Hanson, S. A. Uryu, J. Molina and S. K. Mitra: Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression. J Biol Chem, 282, 17450-17459 (2007)
108. H. Abedi and I. Zachary: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem, 272, 15442-15551 (1997)
109. R. Abu-Ghazaleh, J. Kabir, H. Jia, M. Lobo and I. Zachary: Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J, 360, 255-264 (2001)
110. S. M. Weis, S.-T. Lim, K. M. Lutu-Fuga, L. A. Barnes, X. L. Chen, J. R. Gothert, T.-L. Shen, J.-L. Guan, D. D. Schlaepfer and D. A. Cheresh: Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J. Cell Biol., 181, 43-50 (2008)
111. B. Tavora, S. Batista, L. E. Reynolds, S. Jadeja, S. Robinson, V. Kostourou, I. Hart, M. Fruttiger, M. Parsons and K. M. Hodivala-Dilke: Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med, 2, 516-528 (2010)
112. V. Kostourou, T. Lechertier, L. E. Reynolds, D. M. Lees, M. Baker, D. T. Jones, B. Tavora, A. R. Ramjaun, G. M. Birdsey, S. D. Robinson, M. Parsons, A. M. Randi, I. R. Hart and K. Hodivala-Dilke: FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun, 4, 2020 (2013)
113. V. M. Golubovskaya, C. Virnig and W. G. Cance: TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog, 47, 222-234 (2008)
114. T.-J. Liu, T. LaFortune, T. Honda, O. Ohmori, S. Hatakeyama, T. Meyer, D. Jackson, J. de Groot and W. K. A. Yung: Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther, 6, 1357-1367 (2007)
115. Q. Shi, A. B. Hjelmeland, S. T. Keir, L. Song, S. Wickman, D. Jackson, O. Ohmori, D. D. Bigner, H. S. Friedman and J. N. Rich: A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog, 46, 488-496 (2007)
116. H. S. Choi, Z. Wang, W. Richmond, X. He, K. Yang, T. Jiang, D. Karanewsky, X. J. Gu, V. Zhou, Y. Liu, J. Che, C. C. Lee, J. Caldwell, T. Kanazawa, I. Umemura, N. Matsuura, O. Ohmori, T. Honda, N. Gray and Y. He: Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorg Med Chem Lett, 16, 2689-2692 (2006)
117. T. Heinrich, J. Seenisamy, L. Emmanuvel, S. S. Kulkarni, J. Bomke, F. Rohdich, H. Greiner, C. Esdar, M. Krier, U. Gradler and D. Musil: Fragment-Based Discovery of New Highly Substituted 1H-Pyrrolo[2,3-b]- and 3H-Imidazolo[4,5-b]- Pyridines as Focal Adhesion Kinase Inhibitors. J Med Chem 56, 1160-1170 (2013)
118. J. K. Slack-Davis, K. H. Martin, R. W. Tilghman, M. Iwanicki, E. J. Ung, C. Autry, M. J. Luzzio, B. Cooper, J. C. Kath, W. G. Roberts and J. T. Parsons: Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem, 282, 14845-14852 (2007)
119. W. G. Roberts, E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E. Emerson, J. Lin, J. Kath, K. Coleman, L. Yao, L. Martinez-Alsina, M. Lorenzen, M. Berliner, M. Luzzio, N. Patel, E. Schmitt, S. LaGreca, J. Jani, M. Wessel, E. Marr, M. Griffor and F. Vajdos: Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 68, 1935-1944 (2008)
120. I. Tanjoni, C. Walsh, S. Uryu, A. Tomar, J. O. Nam, A. Mielgo, S. T. Lim, C. Liang, M. Koenig, C. Sun, N. Patel, C. Kwok, G. McMahon, D. G. Stupack and D. D. Schlaepfer: PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther, 9, 764-777 (2010)
121. C. Walsh, I. Tanjoni, S. Uryu, A. Tomar, J. O. Nam, H. Luo, A. Phillips, N. Patel, C. Kwok, G. McMahon, D. G. Stupack and D. D. Schlaepfer: Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther, 9, 778-790 (2010)
122. J. Halder, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, T. Honda, A. A. Kamat, L. Y. Han, T. J. Kim, C. Lu, A. M. Tari, W. Bornmann, A. Fernandez, G. Lopez-Berestein and A. K. Sood: Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res, 67, 10976-10983 (2007)
123. W. Liu, D. A. Bloom, W. G. Cance, E. V. Kurenova, V. M. Golubovskaya and S. N. Hochwald: FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis, 29, 1096-1107 (2008)
124. S. Hehlgans, I. Lange, I. Eke and N. Cordes: 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226. Radiother Oncol, 92, 371-378 (2009)
125. C. S. Smith, V. M. Golubovskaya, E. Peck, L. H. Xu, B. P. Monia, X. Yang and W. G. Cance: Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res, 15, 357-362 (2005)
126. J. B. Stokes, S. J. Adair, J. K. Slack-Davis, D. M. Walters, R. W. Tilghman, E. D. Hershey, B. Lowrey, K. S. Thomas, A. H. Bouton, R. F. Hwang, E. B. Stelow, J. T. Parsons and T. W. Bauer: Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther, 10, 2135-45 (2011)
127. V. M. Golubovskaya, C. Nyberg, M. Zheng, F. Kweh, A. Magis, D. Ostrov and W. G. Cance: A Small Molecule Inhibitor, 1,2,4,5-Benzenetetraamine Tetrahydrochloride, Targeting the Y397 Site of Focal Adhesion Kinase Decreases Tumor Growth. J Med Chem 51, 7405-7416 (2008)
128. E. A. Beierle, X. Ma, J. Stewart, C. Nyberg, A. Trujillo, W. G. Cance and V. M. Golubovskaya: Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle, 9, 1005-1015 (2010)
129. S. N. Hochwald, C. Nyberg, M. Zheng, D. Zheng, C. Wood, N. A. Massoll, A. Magis, D. Ostrov, W. G. Cance and V. M. Golubovskaya: A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle, 8, 2435-2443 (2009)
130. M. Heffler, V. M. Golubovskaya, K. M. Dunn and W. Cance: Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy. Cancer Biol Ther, 14, 761-772 (2013)
131. S. T. Lim, X. L. Chen, A. Tomar, N. L. Miller, J. Yoo and D. D. Schlaepfer: Knockin mutation reveals an essential role for focal adhesion kinase (FAK) activity in blood vessel morphogenesis, cell motility-polarity, but not cell proliferation. J Biol Chem 285, 21526-21536 (2010)
132. J. M. Corsi, C. Houbron, P. Billuart, I. Brunet, K. Bouvree, A. Eichmann, J. A. Girault and H. Enslen: Autophosphorylation-independent and dependent functions of Focal Adhesion Kinase during development. J Biol Chem 284, 34769-34776 (2009)
133. M. Iwatani, H. Iwata, A. Okabe, R. J. Skene, N. Tomita, Y. Hayashi, Y. Aramaki, D. J. Hosfield, A. Hori, A. Baba and H. Miki: Discovery and characterization of novel allosteric FAK inhibitors. Eur J Med Chem 61, 49-60 (2012)
134. E. V. Kurenova, D. L. Hunt, D. He, A. T. Magis, D. A. Ostrov and W. G. Cance: Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in vivo. J Med Chem 52, 4716-4724 (2009)
135. D. A. Ucar, E. Kurenova, T. J. Garrett, W. G. Cance, C. Nyberg, A. Cox, N. Massoll, D. A. Ostrov, N. Lawrence, S. M. Sebti, M. Zajac-Kaye and S. N. Hochwald: Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle, 11, 3250-3259 (2012)
136. D. A. Ucar, A. T. Magis, D. H. He, N. J. Lawrence, S. M. Sebti, E. Kurenova, M. Zajac-Kaye, J. Zhang and S. N. Hochwald: Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem, 13, 595-602 (2013)
137. V. Golubovskaya, N. L. Palma, M. Zheng, B. Ho, A. Magis, D. Ostrov and W. G. Cance: A Small-Molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK And Mdm-2 Interaction, And Blocks Breast And Colon Tumorigenesis In vivo. Anticancer Agents Med Chem 13, 532-545 (2013)
138. V. M. Golubovskaya, B. Ho, M. Zheng, A. Magis, D. Ostrov, C. Morrison and W. G. Cance: Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer, 13, 342-346 (2013)
139. V. Golubovskaya, L. Beviglia, L. H. Xu, H. S. Earp, 3rd, R. Craven and W. Cance: Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem, 277, 38978-38987 (2002)
140. V. M. Golubovskaya, S. Gross, A. S. Kaur, R. I. Wilson, L. H. Xu, X. H. Yang and W. G. Cance: Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol Cancer Res, 1, 755-764 (2003)
141. C. M. Bagi, J. Christensen, D. P. Cohen, W. G. Roberts, D. Wilkie, T. Swanson, T. Tuthill and C. J. Andresen: Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther, 8, 856-865 (2009)
142. V. Golubovskaya, G. Huang, B. Ho, M. Yemma, C. D. Morrison, J. Lee, B. Eliceiri and W. G. Cance: Pharmacological blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 12, 162-172 (2013)
143. V. Bolos, J. M. Gasent, S. Lopez-Tarruella and E. Grande: The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther, 3, 83-97 (2010)
144. Z. Xing, H. C. Chen, J. K. Nowlen, S. J. Taylor, D. Shalloway and J. L. Guan: Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell, 5, 413-421 (1994)
145. H. C. Chen and J. L. Guan: Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A, 91, 10148-52 (1994)
146. D. D. Schlaepfer, S. K. Hanks, T. Hunter and P. van der Geer: Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 372, 786-791 (1994)
147. S. Avraham, R. London, Y. Fu, S. Ota, D. Hiregowdara, J. Li, S. Jiang, L. M. Pasztor, R. A. White, J. E. Groopman and et al.: Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem, 270, 27742-27751 (1995)
148. S. Lev, H. Moreno, R. Martinez, P. Canoll, E. Peles, J. M. Musacchio, G. D. Plowman, B. Rudy and J. Schlessinger: Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature, 376(6543), 737-745 (1995)
149. H. Sasaki, K. Nagura, M. Ishino, H. Tobioka, K. Kotani and T. Sasaki: Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem, 270, 21206-21219 (1995)
150. J. D. Hildebrand, M. D. Schaller and J. T. Parsons: Paxillin, a tyrosine phosphorylated focal adhesion-associated protein binds to the carboxyl terminal domain of focal adhesion kinase. Molecular Biology of the Cell, 6, 637-647 (1995)
151. M. B. Calalb, T. R. Polte and S. K. Hanks: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Molecular & Cellular Biology, 15, 954-963 (1995)
152. M. T. Harte, J. D. Hildebrand, M. R. Burnham, A. H. Bouton and J. T. Parsons: p130cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. Journal of Biological Chemistry, 271, 13649-13655 (1996)
153. A. Richardson, R. K. Malik, J. D. Hildebrand and J. T. Parsons: Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation. Mol Cell Biol, 17, 6906-6914 (1997)
154. J. M. Taylor, J. D. Hildebrand, C. P. Mack, M. E. Cox and J. T. Parsons: Characterization of graf, the GTPase-activating protein for rho associated with focal adhesion kinase. Phosphorylation and possible regulation by mitogen-activated protein kinase. J Biol Chem, 273, 8063-8070 (1998)
155. J. Zhao, R. Pestell and J. L. Guan: Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol Biol Cell, 12, 4066-4077 (2001)